Henry Meds vs Sequence 2026: GLP-1 Weight Loss Programs Compared

Head-to-Head Comparison Table

The following table compares Henry Meds, Sequence, and Trimi across the factors that matter most for patients choosing a GLP-1 weight loss provider. All pricing reflects data observed in early 2026.

Pricing Comparison: What You Actually Pay Over 12 Months

Pricing is the most immediately visible difference between Henry Meds and Sequence, and it reflects their fundamentally different value propositions. Henry Meds positions itself as a competitive-price medication access platform. Sequence positions itself as a premium physician-led program. Both are significantly more expensive than providers like Trimi that offer the same active medications at lower price points. GLP-1 therapy is not a short-term commitment — most patients need 6 to 12 months of continuous treatment to reach their weight loss goals, and many continue maintenance dosing indefinitely. Monthly cost differences compound into thousands of dollars over a typical treatment course.

Henry Meds prices compounded semaglutide between approximately $199 and $349 per month depending on dose tier and plan structure. Their tirzepatide pricing ranges from $299 to $449 per month. On top of these monthly medication costs, Henry Meds charges a separate consultation fee of $49 to $99 for initial provider evaluations. This means a new Henry Meds patient starting semaglutide could pay $248 to $448 in their first month before any medication arrives. Over 12 months on semaglutide, a Henry Meds patient at the mid-range pays approximately $2,388 to $4,188 plus the initial consultation fee. For tirzepatide, the 12-month total ranges from $3,588 to $5,388 or more.

Sequence prices compounded semaglutide between approximately $249 and $399 per month, with tirzepatide ranging from $349 to $399 per month. Sequence generally bundles consultation costs into the plan price rather than charging them separately, which simplifies the cost calculation but results in a higher baseline monthly rate. Some Sequence plans involve quarterly or multi-month commitments that may reduce the per-month rate but require upfront financial commitment. Over 12 months on semaglutide, a Sequence patient pays approximately $2,988 to $4,788. For tirzepatide, the annual total ranges from $4,188 to $4,788.

At Trimi, compounded semaglutide costs $99 per month and compounded tirzepatide costs $125 per month. There is no consultation fee, no enrollment fee, and no contract. A patient taking semaglutide for 12 months at Trimi pays $1,188 total. The same patient at Henry Meds pays $2,388 to $4,188 or more. At Sequence, that figure ranges from $2,988 to $4,788 — meaning the annual difference between Trimi and Sequence can exceed $3,600. For patients weighing the cheapest GLP-1 options in 2026, this pricing gap is substantial enough to influence provider selection for most budgets.

Medications and Access: What Each Platform Prescribes

Both Henry Meds and Sequence prescribe compounded versions of the two most clinically proven GLP-1 weight loss medications: semaglutide and tirzepatide. The active ingredients are identical to those in the brand-name products Wegovy, Ozempic, Zepbound, and Mounjaro. Compounded medications are prepared by accredited pharmacies under FDA-regulated conditions, and the pharmacological effect is the same regardless of which telehealth platform facilitates the prescription. This is the fundamental reality that makes provider comparisons primarily about cost and service — not about medication quality.

Henry Meds offers both compounded semaglutide and compounded tirzepatide as their primary weight loss offerings. Their medication-focused model means the platform is built around getting prescriptions written and medications shipped efficiently. Henry Meds works with compounding pharmacy partners to maintain supply, and medications are delivered directly to patients. The platform handles refills and dose adjustments through their web-based system, though the depth of clinical guidance around those adjustments varies by the individual provider assigned to your case.

Sequence similarly offers both compounded semaglutide and compounded tirzepatide. Where Sequence differs is in the clinical framework surrounding the prescription. Sequence's physician-led model means dose titration decisions are made within a more structured protocol, with providers who specialize in obesity medicine guiding the escalation schedule. Sequence may also coordinate branded GLP-1 prescriptions for patients who have insurance coverage, providing a pathway to brand-name Wegovy or Zepbound through traditional pharmacy channels when coverage allows. This dual-track approach gives Sequence patients more medication pathway options, though the compounded formulations remain the primary offering for cash-pay patients.

Trimi offers both compounded semaglutide and compounded tirzepatide as core offerings with consistent availability. Because Trimi focuses specifically on metabolic health and GLP-1 therapy, medication supply continuity is a central operational priority. Patients who start with semaglutide and later want to transition to tirzepatide — or vice versa based on response and tolerability — can do so seamlessly within the same platform and provider relationship. For patients researching side effect profiles, our guides on Henry Meds side effects and Sequence side effects cover what to expect from each platform's medication protocols.

Provider Model Comparison: Medication Access vs Clinical Program

The provider model is where Henry Meds and Sequence diverge most significantly, and it represents the core trade-off patients must evaluate when choosing between these platforms. GLP-1 therapy involves dose titration decisions, side effect management, treatment duration planning, and ongoing clinical monitoring — all of which benefit from provider expertise and engagement. The question is how much clinical infrastructure you need around your treatment and how much you are willing to pay for it.

Henry Meds operates primarily as a medication access platform. Patients complete a web-based health questionnaire, a licensed provider reviews the submission, and if appropriate, a prescription is issued. The initial consultation may include a video or phone call depending on the plan, which is why Henry Meds charges the separate $49 to $99 consultation fee. After the initial prescription, ongoing provider interactions are generally limited to prescription renewals and basic dose adjustment requests. This model works well for patients who understand GLP-1 therapy, are comfortable self-managing common side effects, and primarily need affordable medication access rather than comprehensive clinical guidance. For patients who want to learn more about what to expect, our Henry Meds side effects guide covers the common issues patients report.

Sequence operates as a structured clinical program. Their provider roster emphasizes board-certified obesity medicine specialists — physicians who have completed additional fellowship training or certification specifically in metabolic health and weight management. This specialization translates into more structured dose titration protocols, more frequent provider check-ins, and a treatment approach that considers metabolic factors beyond just the number on the scale. Sequence's model includes scheduled follow-up appointments and proactive clinical outreach, which can improve outcomes for patients who benefit from external accountability and expert guidance through the treatment process. The trade-off is the premium pricing that funds this level of clinical infrastructure.

Trimi's model falls between these two approaches in structure but delivers dedicated weight management expertise at the most affordable price point. Trimi providers focus specifically on metabolic health and GLP-1 therapy, providing the clinical specialization that generalist platforms lack without the premium pricing of Sequence's comprehensive program model. Patients can communicate directly with their care team for dose questions, side effect guidance, and treatment adjustments through Trimi's web and messaging system without additional fees. This focused approach means patients get knowledgeable clinical support from providers who manage GLP-1 cases daily, not occasionally between other health categories.

Clinical Evidence: The Medication Drives Results, Not the Platform

A critical point that sometimes gets lost in provider comparisons: your weight loss outcomes are determined by the medication, the dose, and your adherence to treatment — not which telehealth brand delivered the prescription. The clinical evidence supporting GLP-1 medications for weight loss is extensive and entirely platform-independent. Neither Henry Meds nor Sequence has proprietary medications. Both prescribe the same compounded formulations of the same active ingredients studied in the same clinical trials.

The STEP 1 trial, published by Wilding et al. in the New England Journal of Medicine in 2021, randomized 1,961 adults with obesity or overweight to semaglutide 2.4 mg weekly or placebo. Over 68 weeks, participants receiving semaglutide lost an average of 14.9 percent of their body weight compared to 2.4 percent in the placebo group. This landmark study established semaglutide as one of the most effective pharmaceutical interventions for weight management ever studied, with efficacy far exceeding older weight loss medications and rivaling surgical outcomes for some patients.

The SURMOUNT-1 trial, published by Jastreboff et al. in the New England Journal of Medicine in 2022, evaluated tirzepatide in 2,539 adults with obesity. The highest dose group (15 mg weekly) achieved an average weight reduction of 22.5 percent of body weight over 72 weeks — the largest average weight loss ever recorded in a pharmaceutical obesity trial. Tirzepatide's dual mechanism as both a GIP and GLP-1 receptor agonist produces additive metabolic benefits beyond what GLP-1 stimulation alone achieves, including greater improvements in insulin sensitivity and cardiovascular risk markers.

Additional evidence from the SELECT cardiovascular outcomes trial (Lincoff et al., NEJM, 2023) demonstrated that semaglutide reduced major adverse cardiovascular events by 20 percent in adults with overweight or obesity and established cardiovascular disease. The STEP 5 trial showed sustained weight loss maintenance over 2 years of continued semaglutide therapy. These results reinforce that GLP-1 medications deliver robust, clinically meaningful outcomes that extend well beyond weight reduction alone.

These results apply equally whether the medication comes from Henry Meds, Sequence, Trimi, or any other legitimate provider prescribing the same active ingredients at the same doses. The compounded versions of semaglutide and tirzepatide contain the identical active pharmaceutical ingredient as the brand-name products studied in these trials. What a good provider adds is not better medication — the medication is the same — but better clinical guidance on dose titration, side effect management, and long-term treatment strategy. That guidance should not cost thousands of dollars more per year when providers like Trimi deliver it at $99 per month.

Where Henry Meds Has the Edge

Henry Meds has legitimate advantages for certain patient profiles, particularly those who prioritize medication access efficiency and lower relative pricing within the premium telehealth segment.

Where Sequence Has the Edge

Sequence has genuine clinical advantages for patients who need or prefer a more comprehensive, physician-directed weight management program and are willing to pay the premium for that level of care.

Shared Limitations of Both Platforms

Despite their respective strengths, Henry Meds and Sequence share fundamental limitations that patients should consider before committing to either platform for long-term GLP-1 therapy.

Why Trimi Compares Favorably to Both

For patients whose primary criteria are effective GLP-1 medication at the lowest sustainable price with quality clinical support, Trimi addresses the key cost and specialization gaps in both the Henry Meds and Sequence models. At $99 per month for compounded semaglutide and $125 per month for compounded tirzepatide, Trimi's everyday pricing undercuts both competitors without requiring promotional codes, multi-month commitments, or limited-time introductory offers.

The core argument is straightforward: the medication produces the results, and the medication is identical across all three platforms. Henry Meds gives you medication access without much clinical support. Sequence gives you premium clinical support at a premium price. Trimi gives you dedicated weight management clinical support at the lowest price point available from an established provider. For most patients, that combination — specialized care plus affordable pricing — is the optimal balance. For patients considering switching, our guides on canceling Henry Meds and canceling Sequence walk through the transition process step by step.

The Bottom Line

Henry Meds and Sequence represent two legitimate but fundamentally different approaches to GLP-1 telehealth. Henry Meds is the better choice if you are choosing only between these two and prioritize lower cost, since its semaglutide pricing starts lower than Sequence's despite the added consultation fee. Sequence is the better choice if you specifically want board-certified obesity medicine physicians directing your care and are willing to pay the highest prices in the compounded GLP-1 market for that level of clinical programming.

However, neither platform justifies its pricing when evaluated against the broader GLP-1 provider market. The medications are identical across all platforms — compounded semaglutide is compounded semaglutide regardless of which telehealth brand ships it. Trimi offers the same active medications at $99 per month for semaglutide and $125 per month for tirzepatide, with no consultation fees, no contracts, and providers who specialize in weight management. Over a 12-month treatment course, the savings compared to either Henry Meds or Sequence are meaningful enough to fund additional health investments or simply reduce the financial burden of long-term treatment.

We encourage patients to verify current pricing directly on each platform's website before committing. Compare total annual cost at your expected maintenance dose, not introductory prices at the lowest dose. For a broader view of the GLP-1 provider landscape, see our cheapest GLP-1 injections in 2026 and our guide to semaglutide treatment at Trimi.